Print

[Rhokia]

https://twitter.com/Dave_it_up/status/1782154024726257748

[*quote*]
David it up! @Dave_it_up

Viral Persistence from COVID-19?

In a recent interview, the head of the NIH mentioned that they now believe viral persistence is one of the major contributors to long-term COVID-19. Studies are now starting to point to the possibility of viral persistence of Sars-cov 2. Why is it so controversial when there are several viruses that persist?

Viruses That Persist 
1. Herpesviruses: These include Herpes Simplex Virus (HSV), Which persists in neuronal cells (nerve tissue near the spine for HSV-1 and sacral ganglia for HSV-2). Varicella-Zoster Virus (VZV): It persists in the dorsal root ganglia and can reactivate to cause shingles.

- Epstein-Barr Virus (EBV): It can persist in B cells and has the potential to reactivate under certain immunocompromised conditions.
   
- Cytomegalovirus (CMV): Typically persists within the salivary glands and other tissues.    2. Human Immunodeficiency Virus (HIV): Persists in various cellular reservoirs, including CD4+ T cells, macrophages, and potentially CNS tissue.   

3. Hepatitis B and C Viruses (HBV and HCV): These viruses primarily persist in liver cells. Chronic infection can lead to liver cirrhosis or cancer.   

4. Papillomaviruses: Persist in the skin and mucosal tissues, potentially leading to the development of warts and other lesions and, in some cases, malignancies like cervical cancer.   

5. JC Virus: Generally persists in the kidneys but can become reactivated and progress to the brain, causing progressive multifocal leukoencephalopathy (PML) in immunocompromised individuals.   

So why do some viruses persist?  It starts with immune-privileged sites. Immune privilege sites are areas in the body where the immune response is either partially or completely suppressed, making them less accessible to the normal immune surveillance mechanisms.   
This unique attribute is designed to protect delicate tissues from potential damage that could occur from a typical inflammatory immune response. However, these sites can also provide a sanctuary for viruses to persist, sometimes for the lifetime of the host.   

Immune Privilege Sites
1. The Central Nervous System (CNS): This includes the brain and spinal cord, which are protected by the blood-brain barrier. 

2. The Eyes: Specifically, the subretinal space and the anterior chamber, which limits immune cell access. 

3. The Testes and Ovaries: These organs limit immune responses to protect developing reproductive cells. 

4. The Placenta: Acts to protect the fetus from maternal immune responses during pregnancy. 

5. The Bone Marrow is an important site for the generation of immune cells, but it is also regulated to prevent immune attack. 

6. The Cochlea: The part of the inner ear involved in hearing, protected to prevent damage that could result in hearing loss. 

7. Pregnancy-Decidua Interface: The lining of the uterus during pregnancy, similar to the placenta, it is crucial for protecting the fetus.   

Treatments
Many persistent viruses are difficult to treat. One issue is that medications have a hard time getting to the locations, and when they do, they’re not as effective.

The difficulty in treating immune-privileged sites with drugs stems from several intrinsic and functional characteristics of these areas. Here are the main reasons why these sites are challenging to target with therapeutic interventions:   

1. Physical Barriers: Many immune-privileged sites are protected by physical barriers that restrict the entry of substances from the bloodstream. For example, the blood-brain barrier (BBB) protects the CNS by tightly regulating the passage of molecules between the bloodstream and the brain tissue. This barrier is highly selective and prevents many drugs from reaching therapeutic concentrations within the CNS. Similarly, the blood-testis and blood-retinal barriers protect the testes and eyes, respectively, limiting drug access.   

2. Reduced Immune Surveillance: The immune system itself is either suppressed or partially inactive in these areas to prevent damage to sensitive tissues. While this suppression protects tissues from autoimmune reactions and inflammation, it also means that the natural immune mechanisms that help clear infections are less effective. This makes it challenging to leverage the usual immune-mediated clearance of pathogens, including viruses, in these areas.   

3. Specialized Microenvironment: Immune-privileged sites often have a unique microenvironment that supports the specific function of the tissue, such as vision in the eye or sperm production in the testes. These specialized conditions can alter how drugs are metabolized or how effective they are within these tissues.   

4. Lack of Lymphatic Drainage: Some immune-privileged sites, like the CNS, have limited or no direct lymphatic drainage, which affects the ability of immune cells to enter and exit these regions. This isolation not only impedes the natural immune response but also complicates the delivery and effectiveness of immunotherapeutic agents.   

5. Drug Toxicity and Side Effects: The tissues in immune-privileged sites are often highly delicate and susceptible to damage. Consequently, there is a higher risk of severe side effects if drugs are administered in doses sufficient to cross-protective barriers. This necessitates a careful balance between drug efficacy and toxicity, often limiting the use of potent drugs that could damage sensitive tissues.   

6. Specificity of Drug Targeting: Designing drugs that can specifically target these areas without affecting other parts of the body is a significant challenge. This requires advanced delivery systems or modification of drugs to ensure they can cross-protective barriers and act only within the desired site.   

7. Ethical and Safety Considerations: Due to the critical functions of many immune-privileged sites (like vision, cognition, and reproduction), there are stringent safety and ethical considerations in conducting research and trials for treatments targeting these areas. This can slow the development and approval of new therapeutic approaches.    Because of these challenges, developing effective antivirals for immune-privileged sites often requires strategies such as designing drugs with higher penetration abilities, using nanotechnology for targeted delivery, or employing local rather than systemic drug administration. Each approach must be tailored to the specific characteristics and needs of the targeted immune-privileged site.
Virus attacking a nerve
11:06 PM · Apr 21, 2024
·
59.8K
 Views
Joana Doe

David it up!
@Dave_it_up
·
18h
What are some of the studies?

The first result[1] discusses how scientists have found SARS-CoV-2 proteins persisting in the blood of some Long COVID patients, even months after initial infection. A study at Brigham and Women's Hospital found viral proteins in 24 out of 37 Long
Show more
David it up!
@Dave_it_up
·
16h
Video Version with audio.
Embedded video
Department of Culture and Tourism - Abu Dhabi
@dctabudhabi
Ad
The Tourism Strategy 2030 marks a pivotal moment in Abu Dhabi's transformative journey.
Embedded video
Teresa Maritano-Aquino
@TMaritanoAquino
·
17h
Thank you for putting this together, Dave. It’s exactly what I need to send to friends & family (despite swearing off of doing so again).
A cousin with a recent cervical cancer diagnosis sent a group message expressing surprise that HPV is responsible. Maybe now they’ll get it.
David it up!
@Dave_it_up
·
16h
Glad to! If you need an audio version, just let me know, and I can throw it into my audio tool and post it on YouTube.

Btw, there is a great book called How Minds Change. It gives some good advice on how to change peoples minds, and not set off their limbic system.
[*/quote*]

[Yuriki]

Das muß ich kurz ausleihen. Wir haben da nämlich ein Problem: WORAN sind die Frauen gestorben?

Warum wurden die geimpft? Was ist vorher passiert? In der Zeit einer Pandemie ist so eine Studie eine sehr heikle Angelegenheit. Was ist durch die Impfung passiert und was durch die Pandemie? Welche Wechselwirkungen gibt es? Vor allem Wechselwirkungen gegen Folgen von SarsCoV2! Was ist da los?

Wir haben ein Problem. Und was für eines!!! Artikel bei https://www.diepresse.com/ lesen, ob da noch mehr zu entdecken ist.

[*quote*]
Medizin
Impfung gegen Brustkrebs zeigt klare Wirkung

Die Ergebnisse der Studie könnten die Behandlung von Brustkrebs revolutionieren. Anne-Christine Poujoulat/AFP via Getty Images
05.06.2024 um 14:26
von Julia Riedl

Eine österreichische Studie konnte erstmals durchschlagende Ergebnisse im Kampf gegen das Mammakarzinom erzielen: Die Sterblichkeit aller geimpften Probandinnen halbierte sich.

„Die Ergebnisse sind spektakulär“, so Christian F. Singer, Professor für klinisch-translationelle gynäkologische Onkologie an der Med-Uni Wien und Leiter einer Brustkrebs-Studie, die seit 2012 in 17 Spitälern in ganz Österreich durchgeführt wurde. Die Ärztinnen und Ärzte überprüften dabei die Wirkung eines neuen Impfstoffs, der das Immunsystem gegen bösartige Geschwülste in der Brust aktivieren soll.

Weniger Todesfälle

Die endgültige Auswertung der Daten aller 400 Teilnehmerinnen wurde diese Woche beim weltgrößten Kongress für Klinische Onkologie in Chicago (USA) präsentiert. Die Ergebnisse könnten die Behandlung von Brustkrebs – sowie auch von weiteren Krebsformen – revolutionieren. Führte doch der weltweit erste erfolgreiche Einsatz einer Impfung zur Behandlung von Brustkrebs zu einer Halbierung der Sterblichkeit aller geimpften Probandinnen sowie zu einer starken Reduzierung der Metastasenbildung. Und das bei verschiedensten Typen von Brustkrebs im Frühstadium.

„Das ist wirksamer als alle neu entwickelten Brustkrebstherapien der letzten Jahre“, erklärt Singer. „Niemand hat einen Effekt in diesem Ausmaß erwartet, weil wir anfangs überhaupt keine Hinweise darauf hatten, dass das Vakzin überhaupt wirkt.“ Denn anfänglich schienen die Resultate eher enttäuschend, der Tumor schrumpfte nach der Vakzingabe nicht mehr also ohne – ähnlich wie bei einigen Studien mit Anti-Krebs-Impfstoffen bisher.

Die Patientinnen wurden jedoch nach der ursprünglichen sechsmonatigen Behandlung weiter beobachtet, und erst nach mehreren Jahren begann sich die Wirkung schließlich zu zeigen: „Nach sieben Jahren waren von den geimpften Frauen noch doppelt so viele am Leben wie in der ­ungeimpften Gruppe“, so Singer. Warum die Impfung nun doch ein so durchschlagender Erfolg wurde, ist allerdings bisher unklar.

Keine Nebenwirkungen

Der Impfstoff richtet sich gegen Muc-1 (Mucin-1), ein Protein, dass an der Oberfläche von 90 Prozent aller Brustkrebstumoren gefunden wird. Schon lang wird versucht, das Immunsystem gegen Muc-1 zu sensibilisieren und damit den Tumor zu bekämpfen, doch bisher ohne Erfolg. In der aktuellen Studie (ABCSG 34), die von der Austrian Breast and Colorectal Cancer Study Group durchgeführt wurde, impfte man die Frauen in einem sehr frühen Stadium der Erkrankung, parallel zur Chemo- oder hormonellen Therapie, jedoch noch vor der Operation des Tumors. Singer: „Eventuell haben wir ein besonders sensibles Zeitfenster gewählt, das speziell für die Immunaktivierung geeignet ist, wobei auch der noch vorhandene Tumor eine Rolle gespielt haben könnte. Hier Erklärungen zu finden wird das Ziel intensiver Forschung der kommenden Jahre sein.“ Auch die spezielle Formulierung des Impfstoffes mit einer besonders immunstimulierenden Lipidhülle ähnlich der von Bakterien könnte zu dem unerwartet starken Effekt beigetragen haben. Ein weiterer Erfolg: Nebenwirkungen blieben aus.

Bevor die Impfung jedoch zur Verfügung steht, müssen die ermutigenden Zahlen noch im Rahmen einer größeren Zulassungsstudie bekräftigt werde. „Wenn die Resultate bestätigt werden, könnte das die Behandlung von Brustkrebs tatsächlich revolutionieren“, hofft Singer. Dann wird sich auch zeigen, ob die Wirkung der Impfung vielleicht sogar noch verstärkt werden kann, wenn sie in Kombination mit anderen neuen immunstimulierenden Therapien gegeben wird.

In Kürze

Eine größere Zulassungsstudie an mehr Patientinnen muss die Ergebnisse nun bestätigen. Nur so kann ein möglicher schädlicher Nebeneffekt ausgeschlossen werden.

Die Kombination mit anderen immunstimulierenden Therapien könnte die Wirkung der Impfung vielleicht verstärken. Dies wurde kürzlich für eine mRNA-Impfung gegen schwarzen Hautkrebs gezeigt.
Lesen Sie mehr zu diesen Themen:
[*/quote*]

HIER MEHR LESEN:
https://www.diepresse.com/18535049/impfung-gegen-brustkrebs-zeigt-klare-wirkung

[Yuriki]

https://x.com/VSicaKasabach/status/1798878878410117474

[*quote*]
--------------------------------------------------
Vanessa Sica Kasabach @VSicaKasabach

"We are completely under-investigating this virus,” said Douglas C. Wallace, a University of Pennsylvania geneticist & evolutionary biologist. “The effects of repeatedly getting this throughout our lives is going to be much more significant than people are thinking.”🎯/1
Image

https://pbs.twimg.com/media/GPbmzO-a4AAf2gj?format=jpg&name=small

--------------------------------------------------
Vanessa Sica Kasabach @VSicaKasabach

“…a University of Colorado team is studying whether covid reawakens dormant cancer cells in mice. Their provocative findings…showed that when mice that were cancer survivors were infected with SARS-CoV-2, dormant cancer cells proliferated in the lungs.”😳/2
Image

https://pbs.twimg.com/media/GPbmzllWAAA_xrR?format=jpg&name=small

2:45 AM · Jun 7, 2024
5,638  Views

--------------------------------------------------
Vanessa Sica Kasabach @VSicaKasabach

“Mitigating risk of infection may be of particular importance for cancer patients. Based on the study’s findings, measures adopted by vulnerable patients…in the early days of the pandemic, wearing masks, avoiding crowded places, getting vaccines, become even more important.”🎯/3
Image

https://pbs.twimg.com/media/GPbmz6jW8AAGN_U?format=jpg&name=small

--------------------------------------------------
Vanessa Sica Kasabach @VSicaKasabach

Link to the WAPO article: https://wapo.st/3Kvhb9d

Link to University of Colorado preprint: https://researchsquare.com/article/rs-4210090/v1


🦠🤺/4

[*/quote*]

[Krik]

Die Verlogenheit der herrschenden politischen Klasse kennt keine Grenzen. Jetzt wird, verursacht durch eben diese mordende herrschende Klasse, das Gesundheitssystem weiter abgewrackt.

Man achte auf die Sprache:

"eine große Belastung für unsere Mitarbeitenden darstellt"

Da ist nicht die Rede von Mitarbeitern, denn das schlösse ALLE ein, sondern es zählen nur noch die, die noch im System mitmalochen. Die Anderen, die Kranken, sind bereits abgeschrieben.

Es ist Krieg. Tote zählen nicht mehr und Kranke auch nicht. Der Moloch Sklavenhalterstaat frißt seine Kinder.

Vor 100 Jahren gab es dazu gute politische Plakate.




https://www.uksh.de/Das+UKSH/Presse/Presseinformationen/2024/UKSH_+Campus+Kiel_+plant+operative+Eingriffe+nach+Dringlichkeit-p-215644.html

[*quote*]
UKSH - Universitätsklinikum Schleswig-Holstein

Campus Kiel - Luftbild 2019_1240x400Campus Luebeck - Luftbild_2019_1240x400

    Startseite
    Das UKSH
    Presse
    Presseinformationen
    2024
    UKSH, Campus Kiel, plant operative Eingriffe nach Dringlichkeit

UKSH, Campus Kiel, plant operative Eingriffe nach Dringlichkeit
Dienstag, 11. Juni 2024

Aufgrund des weiterhin hohen Patientenzuspruchs bei gleichzeitig aktuell eingeschränkter Personalverfügbarkeit muss das Universitätsklinikum Schleswig-Holstein (UKSH), Campus Kiel, die operative Versorgung seiner Patientinnen und Patienten zurzeit nach Dringlichkeit der Therapie planen.

„Wir bitten um Verständnis und bedauern sehr, dass die eingeschränkte stationäre Versorgung mit Wartezeiten und Terminverschiebungen einhergehen muss“, sagt Prof. Dr. Thomas Becker, Ärztlicher Direktor des Campus Kiel. „Dies betrifft insbesondere Eingriffe, die aus medizinischer Sicht unbedenklich verschoben werden können. Die Notfallversorgung bleibt jederzeit sichergestellt.“

Eine Taskforce aus Mitgliedern verschiedener Berufsgruppen arbeitet intensiv an Lösungen, um die Situation möglichst kurzfristig zu entspannen. Betroffene Patientinnen und Patienten werden individuell kontaktiert, um alternative Behandlungstermine zu vereinbaren. „Wir sind uns bewusst, dass diese Situation auch eine große Belastung für unsere Mitarbeitenden darstellt und möchten uns für den unermüdlichen Einsatz herzlich bedanken“, so Prof. Becker.
Verantwortlich für diese Presseinformation:

Oliver Grieve, Pressesprecher des Universitätsklinikums Schleswig-Holstein,
Mobil: 0173 4055 000, E-Mail: oliver.grieve@uksh.de

    Campus Kiel, Arnold-Heller-Straße 3, 24105 Kiel,
    Tel.: 0431 500-10700, Fax: 0431 500-10704
    Campus Lübeck, Ratzeburger Allee 160, 23538 Lübeck,
    Tel.: 0451 500-10700, Fax: 0451 500-10708

Wissen schafft Gesundheit

Christian-Albrechts-Universität zu KielUniversität Kiel
Universität zu LübeckUniversität Lübeck

© 2024, Universitätsklinikum Schleswig-Holstein
[*/quote*]

[Krik]

aus Gründen



https://pbs.twimg.com/media/GP2ni94XQAAq-AP?format=jpg&name=900x900

[Ayumi]

https://pbs.twimg.com/card_img/1797412574901796864/49n8kJkc?format=jpg&name=900x900

Das Bild gehört zu diesem Artikel:

https://www.ineteconomics.org/perspectives/blog/from-long-covid-odds-to-lost-iq-points-ongoing-threats-you-dont-know-about

LESEBEFEHL!

[URL nachgetragen, Krokant]

[Yuriki]

Was soll man davon halten?

"Es muss auch in die Köpfe der Menschen hinein: Ja, die Pandemie ist vorbei. Nein, die Erkrankung ist nicht vom Tisch."

Die Pandemie ist NICHT vorbei. Sie läuft weiter und weiter und weiter. Warum erzählen die Leute so einen unverantwortlichen Blödsinn? WARUM!? Das sind, so wird behauptet, Forscher. Die müssen es doch besser wissen. Wenn Jemand so einen Blödsinn erzählt, zieht er seiner Forschung den Teppich weg. Ich kann solchen Leuten nichts glauben. Gar nichts!

Das Beweisstück von heute, nicht aus der heuteshow, sondern der Hessenschau:


https://www.hessenschau.de/gesellschaft/interview-marburger-post-covid-studie-zeigt-erstaunliche-erfolge-v1,cholesterin-long-covid-100.html?s=08

[*quote*]
    hessenschau.de
    Gesellschaft
    Interview: Marburger Post-Covid-Studie zeigt erstaunliche Erfolge

Interview zu neuer Post-Covid-Studie in Marburg "Symptome deutlich verbessert oder komplett verschwunden"

Veröffentlicht am 16.06.24 um 07:14 Uhr

Audio 00:42 Min. | 14.06.24 |Sonja Fouraté
Neue Studie zu Post Covid

Ein Marburger Forscherteam hat einen neuen Ansatz zur Behandlung von Post-Covid-Symptomen gefunden: Cholesterin- und Blutdruck-Medikamente zeigen erstaunliche Erfolge. Eine Entwarnung vor dem Corona-Virus will Studieninitiator Bernhard Schieffer im Interview aber nicht geben.

Forschende in Marburg sind einen Schritt weitergekommen bei der Linderung von Corona-Spätfolgen: In einer neuen Studie identifizierten sie ein Protein, das bei Post-Covid-Patientinnen und -Patienten verändert ist. Dann behandelten sie diese Menschen mit einer Kombination von Cholesterinsenkern und Medikamenten gegen Bluthochdruck.

Das Resultat: Bei bis zu 90 Prozent der Betroffenen milderten sich die Symptome wie Müdigkeit, Schwindel, Schlafstörungen oder Herzrasen ab oder verschwanden sogar ganz. Bernhard Schieffer, Leiter der Post-Covid-Ambulanz an der Universitätsklinik Marburg und Mitverfasser der Studie, erklärt im Interview, warum das eine gute Nachricht, aber noch keine Heilung von Long- und Post-Covid ist.

Weitere Informationen

Das Gespräch führte Sonja Fouraté. Ende der weiteren Informationen

hessenschau.de:
Herr Professor Schieffer, wo stehen wir im mittlerweile fünften Jahr nach Ausbruch der Corona-Pandemie aus Sicht der Long- oder Post-Covid-Forschung?

Bernhard Schieffer:
Aus Sicht der Long- und Post-Covid-Forschung haben wir es mit zwei Problemen zu tun. Das eine Problem ist, dass jede Corona-Welle weiterhin zwischen acht und 15 Prozent neue Long- oder Post-Covid-Fälle generiert, was laut WHO und RKI auch so bleiben wird. Die Zahlen variieren sehr stark, je nachdem, welche Geschlechts- oder Altersgruppe man anschaut. Das ist ein sehr aktuelles Problem, weil die Menschen nicht mehr akzeptieren, dass es Corona überhaupt noch gibt.

Das zweite Problem ist, dass bei bestimmten Patienten eine Chronifizierung in Richtung einer ME/CFS-Erkrankung droht, dass diese Patienten also dauerhaft krank oder eingeschränkt bleiben. Gemeint sind die Patienten, die während der heißen Phase der Corona-Pandemie bis etwa Ende 2022 infiziert wurden oder die durch den Impfstoff in eine Post-Vac-Symptomatik gestürzt sind. Und die biochemischen Ursachen dieser Chronifizierung kennen wir noch nicht.

hessenschau.de:
Sind Lösungsansätze für die Probleme in Sicht?

Schieffer:
Es gibt unterschiedliche Ansätze. Es gibt die Strategie des Bundesgesundheitsministers, der in den nächsten Wochen unter anderem einen Off-Label-Medikamentenatlas zur Behandlung freigeben möchte (Off-Label-Medikamente werden bei Krankheiten eingesetzt, für die sie eigentlich nicht zugelassen sind, Anm.d.Red.). Außerdem haben das Bundesministerium für Bildung und Forschung und das Bundesministerium für Gesundheit verschiedene Initiativen angestoßen.

Aber, wie das häufig bei wissenschaftlichen Projekten ist: Sie brauchen einfach Zeit. Die Projekte müssen initiiert werden, müssen anlaufen, begutachtet werden. Es ist weltweit viel getan worden, nicht nur in Deutschland, aber die Mühlen mahlen einfach langsam.

hessenschau.de:
Wo setzt nun Ihr aktuelles Forschungsprojekt an?

Schieffer:
Unser Projekt zielt auf die Suche nach neuen Biomarkern, die sich für eine Überwachung von Post-Covid-Patienten eignen (Biomarker sind Merkmale, die im Blut oder Gewebeproben gemessen werden können. Sie können Krankheiten anzeigen, Anm.d.Red.) Wir haben das so genannte HDL identifiziert, das High Density Lipoprotein. Es wird auch das "gute Cholesterin" genannt.

Es ist eines der wenigen Moleküle, das in jedes Organsystem hinein- und wieder hinauswandern kann und Zellabbauprodukte mit sich nimmt. Das ist seine biologische Aufgabe. Es wandert am Ende in die Leber zurück, wo diese Abbauprodukte verstoffwechselt werden.

Die Hypothese unseres interdisziplinären Teams war, dass Veränderungen im Cholesterinstoffwechsel und eine langanhaltende Fehlsteuerung des Blutdrucks zumindest teilweise für Post-Covid- oder Post-Vac-Symptome verantwortlich sein könnten.

hessenschau.de:
Und Ihre Hypothese hat sich bewahrheitet?

Schieffer:
Ja, Hintergrund ist, dass das HDL wie ein Staubsaugerbeutel funktioniert. Es ist für uns ein Blick in die Glaskugel von Post-Covid. Wir finden darin sehr viele aufschlussreiche Moleküle, die auch auf neue biochemische Prozesse hindeuten, die durch Corona beeinträchtigt oder teilweise zerstört werden.

Im Vergleich zu gesunden Kontrollpersonen wies das HDL-Cholesterin der Patientinnen und Patienten signifikante Veränderungen auf. Wir haben den Patientinnen und Patienten dann einen Cholesterinsenker und ein Medikament gegen Bluthochdruck verabreicht.

Vier bis sechs Monate später haben wir die Patientinnen und Patienten nachuntersucht und fast alle - also zwischen 85 und 90 Prozent - haben sich in ihren Symptomen deutlich gebessert oder die Symptome waren komplett verschwunden.

hessenschau.de:
Welche Symptome hatten die Studienteilnehmenden? Es gibt ja eine ganze Bandbreite an Symptomen, die auf Post-Covid oder Post-Vac zurückzuführen sein können.

Schieffer:
Die Frage nach den Symptomen ist eine sehr kritische. Wir haben die Patienten sehr gut ausgewählt. Wir haben die Symptome unserer vielen Patienten mithilfe eines KI-basierten mathematischen Algorithmus bestimmten Clustern zugeordnet. Darauf basierend haben wir die Patienten ausgewählt und sie dieser Therapie zugeführt.

Die Gruppe, die wir hier untersucht haben, hatte eine infektbedingte Fettstoffwechselstörung entwickelt, das ist die größte Gruppe der Patienten.

hessenschau.de:
Es ist aber noch keine ursächliche Post-Covid-Behandlung.

Schieffer:
Es ist ein schnell verfügbarer therapeutischer Ansatz, der gewählt werden kann, um die schlimmsten Symptome zu beseitigen. Wir sprechen nicht davon, dass wir ursächlich arbeiten. Wir wissen noch nicht, wie man das Corona-Virus aus dem Körper bekommt. Das ist so ähnlich wie beim Epstein-Barr-Virus oder wie beim HI-Virus. Die adäquate Entwicklung von Medikamenten für eine solche Erkrankung dauert sehr lange.

hessenschau.de:
Wie weit ist die Ursachenforschung fortgeschritten?

Schieffer:
Wir gehen heute davon aus, dass Covid-19 eine in der Lunge beginnende Erkrankung ist, die sich dann in eine generalisierte Gefäßentzündungserkrankung weiterentwickelt - mit entsprechender Thrombenbildung, mit Störung der Blut-Hirn-Schranke, mit Störung der Gehirndurchblutung und mit entsprechenden Nervenentzündungen.

Daher kommt auch die sehr bunte Post-Covid-Symptomatik von Sehstörungen über Entwicklung von neurodegenerativen Erkrankungen wie MS oder Parkinson bis hin zu entzündungsähnlichen Herz-Muskel-Symptomatiken, Herzschwächen, Elektrolytstörungen am Herzmuskel, und, und, und.

hessenschau.de:
Ist Covid-19 auch der Grund dafür, dass die Dauer der Krankschreibungen im Herbst und Winter zuletzt immer länger wurde?

Schieffer:
Absolut. Das, was wir von grippalen Infekten kennen, die nach fünf bis sieben Tagen mit oder ohne Arzt vorbei sind, das kennen wir von Corona nicht. Es ging auch jetzt wieder durch die Medien, dass der neue Stamm einen sehr verzögerten und sehr langwierigen Heilungsprozess braucht, damit die Patienten wieder halbwegs auf die Beine kommen.

hessenschau.de:
Was brauchen wir vor diesem Hintergrund neben Forschungsgeldern an Ressourcen?

Schieffer:
In Hessen sind wir dabei, ein Zentrum für postinfektiöse Erkrankungen wie Post-Covid zu etablieren. Dafür sind die ersten Gespräche geführt, es gibt die ersten Bekenntnisse dazu, dass wir so etwas brauchen. Wir brauchen es auch für zukünftige Pandemien von noch unbekannten Erregern.

Wir müssen verschiedenste Disziplinen zusammenbringen, die alle gebündelt schnellstmöglich dafür sorgen, dass die Patienten versorgt werden. Das ist auch auf Bundesebene sehr viel Überzeugungsarbeit, aber mir ist es noch nicht passiert, dass ich auf verschlossene Türen oder Ohren gestoßen bin.

Es muss auch in die Köpfe der Menschen hinein: Ja, die Pandemie ist vorbei. Nein, die Erkrankung ist nicht vom Tisch. Wir werden uns die nächsten Jahre, vielleicht Jahrzehnte mit weiteren Stämmen, mit weiteren Mutationen dieser Erkrankung auseinandersetzen müssen. Wir alle, denn Sie können sich jederzeit infizieren.

hessenschau.de:
Das klingt beunruhigend.

Schieffer:
Es geht keinesfalls um Angstmache. Wir verstehen Tag für Tag mehr, aber die Forschung zeigt uns auch, wie langwierig man denken muss, um drei, vier Ecken, und wie transdisziplinär man sich aufstellen muss. Die Biochemie dieser Erkrankung fordert uns komplett heraus.


Weitere Informationen
Bernhard Schieffer

Professor Bernhard Schieffer ist Leiter der Kardiologie am Fachbereich Medizin der Philipps-Universität Marburg. Er hat die Post-Covid-Ambulanz an der Universitätsklinik Marburg aufgebaut. Neben seiner Arbeitsgruppe beteiligten sich weitere Marburger Wissenschaftlerinnen und Wissenschaftler an der Studie.

Sendung: hr4, 17.06.2024, 8.30 Uhr

Quelle: hessenschau.de
[*/quote*]

[Respererso]

CoVid: Die Menschen verblöden vor unseren Augen und wir können nichts dagegen tun

Das ist in diesem Forum der Tenor seit Anfang 2020. Jetzt, mehr als vier Jahre später, sickert das bei einigen Onlinern endlich durch. Stellt Euch vor, die Aliens würden landen. Bis die Menschheit das begriffen hätte, wäre die Erde mindestens 1000x in die Luft gesprengt worden.


https://x.com/drseanmullen/status/1804881869592302039

[*quote*]
Dr. Sean Mullen @drseanmullen

Folks, someone just reached out to me to say this (xxxxx to protect identity)

“…I work with dozens of xxxxx on a regular basis and the impact of Covid is evident and alarming. We've had many xxxxx with formerly stellar performance suddenly begin struggling and dropping the ball on all their work, people forgetting conversations and losing track of their train of thought regularly, and of course the constant waves of illness throughout all our teams. Have even had a couple team leads have to step down because they literally couldn't perform the role anymore.
 
Of course, I can't definitively say it's all from Covid, but it's clear that certain folks are suffering some form of Long Covid. Additionally, some have ongoing major health issues that seem unusual given their young age. I have a few other Covid-cautious friends in leadership roles at other large companies and they're seeing a similar pattern. Massive amounts of sick leave being taken and just general poor performance across the board”

If repeatedly getting infected with a brain-damaging, vascular disease that attacks your immune system and may never leave your body doesn't trigger a high alert to avoid infection, I don't know what will. 🤷‍♂️
4:19 PM · Jun 23, 2024
32.7K Views
[*/quote*]

[Respererso]

"If it can be destroyed by the truth,
it deserves to be destroyed by the truth."



https://pbs.twimg.com/media/GQx4JT8a0AALFVV?format=png&name=small

[Pangwall]

Marke: 40000

[Rhokia]

Diese Meldung von MedScape ist 10 Monate alt. 10 Monate!

Je nachdem, wie man es liest, haben 1/5 der Ärzte LongCovid und können nicht mehr arbeiten -
oder 1/5 der Ärzte, die LongCovid haben, können nicht mehr arbeiten.




https://www.medscape.com/viewarticle/996030?form=fpf

[*quote*]
Medscape
News > Medscape Medical News
One in Five Doctors With Long COVID Can No Longer Work: Survey

Claire Sibonney

August 31, 2023

Editor's note: Find the latest long COVID news and guidance in Medscape's Long COVID Resource Center.

Crippling symptoms, lost careers, and eroded incomes: This is the harsh reality for doctors suffering with long COVID, according to the first major survey of physicians with the condition.

The survey, conducted by the British Medical Association (BMA) and the Long COVID Doctors for Action support group, sheds light on the lingering effects of long COVID on more than 600 chronically ill and disabled doctors with the condition. It also spotlights what they describe as a lack of medical and financial support from their government and employers at the National Health Service (NHS).

"We feel betrayed and abandoned," said Kelly Fearnley, MBChB, chair and co-founder of Long COVID Doctors for Action. "At a time of national crisis, when healthcare workers were asked to step up, we did. When the nation needed us, we stepped up. We put our lives on the line. We put our families' lives on the line. And now that we are injured after knowingly being unprotected and deliberately and repeatedly exposed to a level-three biohazard, we now find ourselves in this position."

Fearnley fell ill while working in a hospital's COVID ward in November 2020. She is one of an estimated two million people in the UK — including thousands of NHS employees — with long COVID. She hasn't been able to return to work in nearly 3 years.

Long COVID affects more than 65 million people worldwide. It is estimated that 1 in 10 people infected with the virus develop long-term symptoms. In the UK, healthcare and social care workers are seven times more likely to have had severe COVID-19 than other types of employees.

Doctors responding to the BMA survey reported a wide range of long COVID symptoms, including fatigue, headaches, muscular pain, nerve damage, joint pain, and respiratory problems.

Among the survey's key findings, 60% of doctors said long COVID has affected their ability to carry out day-to-day tasks on a regular basis. Almost 1 in 5 (18%) said they were no longer able to work, while fewer than 1 in 3 (31%) were working full time. This compares to more than half (57%) of respondents working full time before the onset of their COVID illness — a decline of 46%.

Nearly half (48%) of respondents said they have experienced some form of loss of earnings as a result of long COVID, and almost half of the doctors were never referred to an NHS long COVID clinic. The survey included the following first-person accounts from doctors living with the condition.

    One doctor said: "I nearly lost my life, my home, my partner and my career. I have received little support to help keep these. The impact on my mental health nearly cost [me] my life again."

    A senior consulting physician commented: "Life is absolutely miserable. Every day is a struggle. I wake up exhausted, the insomnia and night terrors are horrendous as I live through my worst fears every night. Any activity such as eating meals, washing etc will mean I have to go to bed for a few hours. I am unable to look after myself or my child, exercise or maintain social relationships. I have no financial security. Long COVID has totally destroyed my life."

    A salaried general practitioner said: "I can no longer work, finances are ruined. I didn't have employment protection so am now unemployed and penniless."

Calls for action from the BMA include the following:

[...]

https://www.medscape.com/viewarticle/996030?form=fpf#vp_2

***    Financial support for doctors and healthcare staff with long COVID;

***    The recognition of long COVID as an occupational disease among healthcare workers, along with a definition of the condition that covers all of the debilitating disease's symptoms;

***    Improved access to physical and mental health services to help comprehensive assessment, investigations, and treatment;

***    Greater workplace protection for healthcare staff who risk their lives for others;

***    Better support for long COVID sufferers to return to work safely if they can, including a flexible approach to the use of workplace adjustments.


"One would think, given the circumstances under which we fell ill and current workforce shortages, NHS employers would be eager to do everything to facilitate the return to work of people with long COVID," said Fearnley. "However, NHS employers are legally required to implement only 'reasonable adjustments,' and so things such as extended phased return or adjustments to shift patterns are not always being facilitated. Instead, an increasing number of employers are choosing to terminate contracts."

Raymond Agius, the BMA's occupational medicine committee co-chair, also put the blame on inadequate safety measures for doctors. Those inadequte measures persist to this day, inasmuch as UK hospitals have dropped masking requirements.

"During the COVID-19 pandemic, doctors were left exposed and unprotected at work," he said in a BMA press release. "They often did not have access to the right PPE.... Too many risk assessments of workplaces and especially of vulnerable doctors were not undertaken."

A small minority of doctors who were surveyed said they had access to respiratory protective equipment (RPE) about the time they contracted COVID-19. Only 11% had access to an FFP2 respirator (the equivalent of an N95 mask); 16% had an FFP3 respirator (the equivalent of an N99 mask).

To date, the British government hasn't issued much of a response to the survey, saying only that it has invested more than ₤50 million to better understand long COVID.

For more news, follow Medscape on Facebook, X, Instagram, and YouTube
[...]
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC. This website also contains material copyrighted by 3rd parties.
[*/quote*]

Ich vermute: PPE = Personal Protective Equipment


Das war vor 10 Monaten. Das war in Großbritannien. Wie ist es dort HEUTE? Wie ist es in Deutschland, in Frankreich, in Spanien, in der Schweiz, in den Niederlanden, in Belgien, in Dänemark, in Finnland, in Litauen, in Lettland, in Estland, in Schweden, in Norwegen? Und vor allem: WIE IST ES IN DER UKRAINE!?

In der Ukraine tobt nicht nur der Angriffskrieg durch Putin, sondern obendrein auch noch die Pandemie. Wie sollen die Ukrainer das durchhalten? Was die Ukrainer leisten, können sich die wohlstandsverwahrlosten deutschen Rötzgören nicht im mindesten vorstellen.

Damals, im August 2023, wurde geschätzt, daß 1/10 aller Infizierten LongCovid bekommen, was nichts anderes bedeutet als STARKE, BLEIBENDE Hirn- und Organschäden.

Das gilt aber doch nur für die 1. Infektion. Was ist bei Folgeinfektionen? Wie stark sind die Folgeinfektionen verteilt?

Wieviele Covid-Infizierte haben (noch) 1 Infektion?
Wieviele haben 2?
Wieviele haben 3?
Wieviele haben 4?
Wieviele haben 5 ?
Wieviele haben 6?
Wieviele haben 7 ?
Wieviele haben 8?
Wieviele haben 9 ?
Wieviele haben 10?
Wieviele haben 11?
Wieviele haben 12?
Wieviele haben 13 ?
Wieviele haben 14?
Wieviele haben 15?
Wieviele haben ...?

Wie stark sind die Schäden und hoch ist der LongCovid-Anteil bei denen mit mehr als nur 1 Infektion?

In dem Artikel sind noch mehr Hämmer.

Zum Beispiel:

"Among the survey's key findings, 60% of doctors said long COVID has affected their ability to carry out day-to-day tasks on a regular basis. Almost 1 in 5 (18%) said they were no longer able to work, while fewer than 1 in 3 (31%) were working full time. This compares to more than half (57%) of respondents working full time before the onset of their COVID illness — a decline of 46%."

1/5 kann überhaupt nicht mehr arbeiten. 1/3 arbeitet Vollzeit. Vollzeit arbeiten trotz LongCovid?

Man kann sagen, was man will, aber der Artikel ist sprachlich böse zusammengeschludert. Man kann einfach nicht erkennen, worauf sich diese Zahlen überhaupt beziehen.

Wenn 1/5 der Ärzte mit LongCovid nicht mehr arbeiten können, bedeutet die zweite Zahl, daß 1/3 mit LongCovid in Vollzeit arbeitet. Kann das sein? Ich habe daran ernste Zweifel.

Doch davon abgesehen, wie ist die Situation in den anderen Ländern? Wie ist sie in Deutschland. Wieviele Ärzte sind hier inzwischen ausgefallen?

Und noch etwas, noch so ein Hammer des staatlichen und privaten Irrsinns: 

"A small minority of doctors who were surveyed said they had access to respiratory protective equipment (RPE) about the time they contracted COVID-19. Only 11% had access to an FFP2 respirator (the equivalent of an N95 mask); 16% had an FFP3 respirator (the equivalent of an N99 mask)."

Das wichtige Faktum: "about the time they contracted COVID-19".

Ärzte wurden befragt. Welche Ärzte? Wer sind diejenigen, die Covid bekamen? Alle Befragten?

11 Prozent hatten FFP2-Masken.
16 Prozent hatten FFP3-Masken.

Das sind zusammen 27 Prozent!

Nicht einmal 1/3 der Ärzte hatten eine ausreichende Maske. Und das bei einer Infektion, die über die Luft übertragen wird.

Wieviele hatten überhaupt eine OP-Maske?

Das ist es, was die Ärzte kritisieren: Man hat sie ohne ausreichenden Schutz in die Arbeit gezwungen und sie verheizt.

Was ist, wenn eine Maske sogar verboten wird? Das haben wir doch! IN DEUTSCHLAND! Taxifahrer, Andere im öffentlichen Raum, UND DANN DIE SCHULKINDER!

Die Politik der herrschenden Klasse verheizt die Menschen bis zum letzten Knochen.

Die sozialkritischen Zeichnungen aus der Zeit vor 100 Jahren über den Moloch "allesfressende Industrie" werden heute von der Realität weit übertroffen.

Es ist Mord. An der ganzen Bevölkerung.

Ausnahmen bestätigen die Regel nicht nur, sondern sie bestimmen sie. Davos-Standard für Alle? Wo kämen wir denn da hin? Nein, der ist nur für die Elite. Für die Führer.

Es ist Mord.

[Wrastrolentiks]

https://x.com/NIHDirector/status/1811786404189602171

[*quote*]
Dr. Monica M. Bertagnolli @NIHDirector

After analyzing data from 200K Americans who had #COVID19 twice, researchers found that a severe #COVID case tended to foreshadow a similarly severe infection the second time, underscoring the importance of preventing infection:
From nih.gov

https://pbs.twimg.com/card_img/1811770767065120769/YSor4QBf?format=jpg&name=4096x4096

https://www.nih.gov/news-events/news-releases/study-suggests-reinfections-virus-causes-covid-19-likely-have-similar-severity-original-infection
5:35 PM · Jul 12, 2024
11.8K Views
[*/quote*]


https://www.nih.gov/news-events/news-releases/study-suggests-reinfections-virus-causes-covid-19-likely-have-similar-severity-original-infection

[*quote*]
U.S. Department of Health & Human Services
National Institutes of Health (NIH) - Turning Discovery into Health
Home » News & Events » News Releases
News Releases

Media Advisory

Thursday, July 11, 2024
Study suggests reinfections from the virus that causes COVID-19 likely have similar severity as original infection

NIH-funded analysis of health record data shows severe reinfections often follow severe first infections.
Novel Coronavirus SARS-CoV-2



https://www.nih.gov/sites/default/files/styles/featured_media_breakpoint-large-extra/public/news-events/news-releases/2024/20240712-sars.jpg?itok=5JL1YFZD&timestamp=1720793111

Colorized scanning electron micrograph of a cell (red) infected with SARS-CoV-2 virus particles (blue), isolated from a patient sample.NIAID
What

Using health data from almost 213,000 Americans who experienced reinfections, researchers have found that severe infections from the virus that causes COVID-19 tend to foreshadow similar severity of infection the next time a person contracts the disease. Additionally, scientists discovered that long COVID was more likely to occur after a first infection compared to a reinfection. The study, funded by the National Institutes of Health’s (NIH) Researching COVID to Enhance Recovery (RECOVER(link is external)) Initiative, is published in Communications Medicine(link is external).

The analysis used data from electronic health records of 3.1 million Americans who are part of the National COVID Cohort Collaborative (N3C). Researchers focused on 212,984 people who reported a reinfection. Those individuals were originally infected between March 1, 2020-Dec. 31, 2022, and experienced a second infection by March 2023. Most participants (203,735) had COVID-19 twice, but a small number (478) had it three times or more. COVID-19 vaccines, though not available during the entire study period, correlated with a protective effect(link is external).

About 27% of those with severe cases, defined as receiving hospital care for a coronavirus infection, also received hospital care for a reinfection. Adults with severe cases were more likely to have underlying health conditions and be ages 60 or older. In contrast, about 87% of those who had mild COVID cases that did not require hospital care the first time also had mild cases of reinfections.

Reinfections were defined as having occurred at least two months after a first infection. They were found to occur most frequently when omicron variants were circulating in late 2021 and early 2022. Waning immunity and increased exposure to the coronavirus, including the highly-infectious variants, likely accounted for the uptick.

Scientists also discovered that regardless of the variant, long COVID cases were more likely to occur after a first infection compared to a reinfection. Long COVID(link is external) was defined in the review as those experiencing long-term COVID-19 symptoms, such as feeling tired, coughing, or having problems sleeping, breathing, or thinking, after an acute coronavirus infection.

Researchers also found that lower levels of albumin, a protein made by the liver, may indicate a higher risk for reinfection. This finding could indicate lower albumin as a possible risk marker for reinfection. Scientists believe this deserves further attention, such as by considering trials to test if nutritional interventions may prevent reinfection or its severity.

The study is funded by NIH’s RECOVER(link is external) Initiative. Additional support came from the N3C Data Enclave(link is external), which is supported by the National Center for Advancing Translational Sciences, also part of NIH.
Who

David C. Goff, M.D., Ph.D., a senior scientific program director for the RECOVER Observational Consortium Steering Committee and director of the Division of Cardiovascular Sciences at the National Heart, Lung, and Blood Institute (NHLBI), part of NIH, is available for interviews on this paper.
Study

Hadley E, Yoo YJ, Patel S, et al. Insights from an N3C RECOVER EHR-based cohort study characterizing SARS-CoV-2 reinfections and Long COVID. Commun Med. 2024; doi: 10.1038/s43856-024-00539-2.(link is external)

HHS Long COVID Coordination: This work is a part of the National Research Action Plan(link is external) (PDF, 1.3 MB), a broader government-wide effort in response to the Presidential Memorandum(link is external) directing the Secretary for the Department of Health and Human Services to mount a full and effective response to long COVID. Led by Assistant Secretary for Health Admiral Rachel Levine, the Plan and its companion Services and Supports for Longer-term Impacts of COVID-19 report(link is external) (PDF, 1.6 MB) lay the groundwork to advance progress in the prevention, diagnosis, treatment, and provision of services for individuals experiencing long COVID.

About RECOVER: The National Institutes of Health Researching COVID to Enhance Recovery (NIH RECOVER) Initiative brings together clinicians, scientists, caregivers, patients, and community members to understand, diagnose, and treat long COVID. RECOVER has created one of the largest and most diverse groups of long COVID study participants in the world. In addition, RECOVER clinical trials are testing potential interventions across five symptom focus areas. For more information, please visit recoverCOVID.org(link is external).

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIH…Turning Discovery Into Health®

###
Institute/Center

National Heart, Lung, and Blood Institute (NHLBI)
Contact
NHLBI Engagement and Media Relations Branch(link sends e-mail)
301-443-5449
Connect with Us

    Subscribe to news releases
    RSS Feed

Connect with Us

    Contact Us X(link is external) Facebook(link is external) Instagram(link is external) YouTube(link is external) Flickr(link is external) More Social Media from NIH

Footer

    NIH Home Virtual Tour En Español Visitor Information Frequently Asked Questions Privacy Policy Disclaimers Accessibility NIH Website Archives

    Nondiscrimination Notice Freedom of Information Act No Fear Act HHS Vulnerability Disclosure(link is external) Office of Inspector General(link is external) USA.gov(link is external)

NIH…Turning Discovery Into Health®
National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892
U.S. Department of Health and Human Services(link is external)
[*/quote*]

[Krik]

https://phys.org/news/2024-08-blowflies-bird-flu-virus.html

[*quote*]
    Biology
    Veterinary medicine

August 1, 2024
Editors' notes
Blowflies found to carry bird flu virus

by Kyushu University
(A) Geographical view of Izumi City, Kagoshima, Japan, and the blowfly collections sites. (B) Schedule of blowfly surveillance. White arrowheads indicate the dates of HPAI cases in poultry farms. Black marks indicate the blowfly collection dates. The line graph depicts the number of dead wild birds in Izumi City, as reported by the Ministry of the Environment, Japan. Credit: Scientific Reports (2024). DOI: 10.1038/s41598-024-61026-1

Researchers from Kyushu University have discovered that blowflies, a family of flies strongly attracted to decaying flesh and feces, are carrying the bird flu virus in southern Japan. Their findings, published in Scientific Reports, introduce a potential new route of transmission for bird flu and  highlight the need to develop new countermeasures to prevent and control the disease in poultry farms.

Since 2020, bird flu has been spreading rapidly around the globe, leading to the death of millions of wild birds and the culling of more than half a billion farmed birds worldwide. In Japan, where a single case of infection on a poultry farm mandates the culling of the entire stock, the 2022–2023 winter season saw a record-high of 326 outbreaks of bird flu, resulting in the sacrifice of 17.7 million birds.
[...]
[*/quote*]


Das ist nicht nur in Japan so, das ist auf der ganzen Erde so! Fliegen übertragen Viren. Das ist nichts Neues, sondern schon lange bekannt.

Wer eine Hühnerfarm hat, muß zwingend Luftfilter einbauen, damit keine Fliegen oder andere Insekten in die Stallungen kommen können.

Eine Garantie für Sicherheit gibt es nicht. Wir sind - bildlich gesprochen - auf der Planke. Jede Sekunde kann es krachen. Ein Zurück gibt es nicht. Und die Zukunft? Ist kohlrabenschwarz.

[Yuriki]

Eine selten dämliche Überschrift leistet sich heute die "Berliner Zeitung", ein Käseblatt, das den Rest des Artikels hinter einer Paywall versteckt. Ist wohl auch besser so. Schon die Überschrift...

"Warum jeder Fünfte noch nie Corona hatte und mancher nach der Impfung erkrankt"

Sehr Ihr, was ich sehe? "noch nie Corona hatte". Noch nie! Das soll ja wohl heißen, daß der Rest, diese übrigen 20 Prozent, diese miese Minderheit, nun endlich auch an Covid19 erkranken soll, aber zackich!


[*quote*]
Gesundheit
Corona: Warum es jeder Fünfte noch nie hatte – und mancher nach der Impfung erkrankt

Warum jeder Fünfte noch nie Corona hatte und mancher nach der Impfung erkrankt

Auch wenn Corona in der Öffentlichkeit nur noch eine zweitrangige Rolle spielt, wird nach wie vor intensiv geforscht. Ein Überblick über offene Fragen und neue Studien.

Author - Torsten Harmsen
07.08.2024 aktualisiert am 08.08.2024 - 09:14 Uhr

Es sieht aus wie in einem Katastrophenfilm: Medizinisches Personal transportiert im März 2020 einen Covid-19-Patienten in den CT-Raum eines Krankenhauses. Über den Ursprung des Virus wird nach wie vor gestritten.
Fei Maohua/dpa

Gibt es noch offene Forschungsfragen zu Corona? Was weiß man heute und was nicht? Das wollte das Science Media Center (SMC) von den deutschen Forschern wissen.

Zu den 26 Wissenschaftlern, die geantwortet haben, gehören Immunologen, Virologen, Epidemiologen, Mikrobiologen, Infektiologen, Experten für Public Health, Internisten, Kinder- und Jugendmediziner und andere. Diese waren bereits 2021 nach ihrer „dringlichsten unbeantworteten Frage“ zu Corona gefragt worden und sollten nun Bilanz ziehen. Hier eine Auswahl.

Unbegrenzt weiterlesen.
[...]
[*/quote*]

https://www.berliner-zeitung.de/gesundheit-oekologie/corona-warum-es-jeder-fuenfte-noch-nie-hatte-und-mancher-nach-der-impfung-erkrankt-li.2240674


Ich halte die Zahl sowieso für falsch. Ich befürchte, daß sie kleiner ist, weil ein Teil der Fälle ohne erkennbare Symptome verläuft, und weil das vor allem bei Kindern so ist, wobei gerade Kinder besonders gefährdet sind und deren "Wehwehchen" sowieso keiner ernst nimmt.

Gehen wir von 20 Prozent aus: wieviele Menschen sind das? In Deutschland sind jetzt vermutlich 84 Millionen Menschen, plus minus. Damit kann man leicht rechnen: 1/5 sind 16,8. Womit die 80 Prozent 4x soviel sind: 64+3,2= 67,2 Millionen. Ungefähr soviel wie die Bundesrepublik hatte (64 Millionen), als sie die DDR übernahm.

67 Millionen Menschen hatten also mindestens 1x Covid19. Also mindestens 1x Dachschaden. Und eine verkürzte restliche Lebenszeit.

Die ganzen Statistiken der Regierungen und der Institute und "Forscher" über "Lebenserwartung" sind bloß noch Müll.

Wenn das RKI im Jahr 2012 seine infame Studie gemacht hat, bei der Millionen Menschen starben, wie ist die Sache weitergegangen? Was haben sie ausgerechnet, wie es weitergeht? Oder haben sie lieber alles weggeschmissen, weil sie es lieber nicht wissen wollten? Das würde ich jetzt aber gerne wissen!

Der Countdown läuft: Wie werden diese 67 Millionen Menschen in den nächsten Jahren verschwinden? Den Firmen geht jetzt schon das Personal aus. Was ist in 1 oder 2 Jahren? Man braucht gar nicht so weit in die Zukunft gucken, 1 oder 2 Jahre reichen. Der Zugverkehr bricht zusammen, der Lieferdienst für Waren aller Art bricht zusammen. Der Mangel an Klopapier wäre noch das kleinste Übel. Wenn die Firmen kein Material kriegen, können sie nichts herstellen (was dann sowieso nicht abgeholt werden würde). Der Staat wäre im Eimer. Ohne Verkäufe keine Steuern, ohne Steuern kein Staatsbetrieb. Die Oberaffen würde sich noch ein paar Jahre halten können, aber dann ginge es denen auch an den Kragen. Auch die Oberaffen brauchen FUTTER UND KLOPAPIER.

Mich erinnert das an die Filmserie "Mad Max". Von der Verwüstung der Erdoberfläche und der Hitze stimmt es schon mal. Von der Blödheit und der Gewalt auch.

[Pangwall]

Wenn selbst die vor Dummheit strotzende WHO katastrophale Zahlen meldet, sieht es übel aus. In einer Pressekonferenz am 6.8.2024 sagte die für die WHO arbeitende Dr. Maria Van Kerkhove:

"Wastewater surveillance suggests that the circulation of SARS-CoV-2 is two to 20 times higher than what is currently being reported."

Wenn Tests nicht gemacht werden, ja, nicht einmal gemacht werden KÖNNEN, weil die Mörderbande "Regierung" dazu die Grundlagen vernichtet, dann kann man doch auch gar nicht wissen, was wirklich los ist. Die deutsche Regierung hat schon letztes Jahr alles in Bewegung gesetzt, damit eine Erfassung der Covid19-Fälle tunlichst zu unterbleiben hat. Und dann beruft sie sich auf Zahlen, die sie selbst auf diese Weise (Untererfassung) gefälscht hat.

Wie auch immer, es läuft eine Riesenwelle. Dabei haben wir noch Sommer. Der Tsunami wird im Winter zuschlagen.


Bei einer Sache können wir live zusehen: "surges of COVID-19, including at the Olympics where at least 40 athletes have tested positive,” Dr. Van Kerkhove said."

40 Vollpfosten hat es bisher erwischt. Ich meine: Wer ist auch so dämlich und fährt zu so einer Veranstaltung, wo sich dann auch noch herausstellt, daß eine ganze Menge Teilnehmer krank angereist ist.

Die hätten niemals dorthin fahren dürfen. Die Funktionäre hätten diese Teilnehmer sofort kaltstellen müssen und sie zuhause lassen müssen. Spätestens bei Krankheitssymptomen hätten diese Vollpfosten gesperrt werden müssen. Nicht irgendwie, sondern auf Lebenszeit, wegen eines terroristischen Anschlags auf das Leben aller anderen Teilnehmer!

Die Organisatoren hätten man sowieso und erst recht verknacken müssen, denn diese Olympiade hätte niemals stattfinden dürfen.

Und jetzt? Jetzt rollt die Infektionswelle durch die ganze Szene. Wer gesund gekommen ist, kommt als Wrack zurück.


Ob die Kader genug Zinksärge mitgebracht haben? Man sollte zählen. Jeden einzelnen Fall, egal ob halbsiech, viertels- oder ganz fertig für den Kompost.


https://www.unognewsroom.org/story/en/2284/covid-19-situation-update-who-06aug2024

[*quote*]
The United Nations Office at Geneva
Multimedia Newsroom
COVID-19 situation update - WHO 06 AUG 2024
/2:19/MP4/172.3 MB

Transcripts
                               
06-08-2024

Edited News | WHO
COVID-19 situation update - WHO - 06 August 2024

COVID-19 makes a worrying comeback, WHO warns amid summertime surge

COVID-19 infections are surging globally, including at the Paris Olympics, and are unlikely to decline anytime soon, the World Health Organization (WHO) says. The UN health agency is also warning that more severe variants of the coronavirus may soon be on the horizon.


“COVID-19 is still very much with us,” and circulating in all countries, Dr. Maria Van Kerkhove of WHO told journalists in Geneva.

“Data from our sentinel-based surveillance system across 84 countries reports that the percent of positive tests for SARS-CoV-2 has been rising over several weeks,” she said. “Overall, test positivity is above 10 per cent, but this fluctuates per region. In Europe, percent positivity is above 20 per cent,” Dr. Van Kerkhove added.

New waves of infection have been registered in the Americas, Europe and Western Pacific. Wastewater surveillance suggests that the circulation of SARS-CoV-2 is two to 20 times higher than what is currently being reported. Such high infection circulation rates in the northern hemisphere’s summer months are atypical for respiratory viruses, which tend to spread mostly in cold temperatures.

“In recent months, regardless of the season, many countries have experienced surges of COVID-19, including at the Olympics where at least 40 athletes have tested positive,” Dr. Van Kerkhove said.

As the virus continues to evolve and spread, there is a growing risk of a more severe strain of the virus that could potentially evade detection systems and be unresponsive to medical intervention. While COVID-19 hospital admissions, including for Intensive Care Units (ICUs), are still much lower than they were during the peak of the pandemic, WHO is urging governments to strengthen their vaccination campaigns, making sure that the highest risk groups get vaccinated once every 12 months.

“As individuals it is important to take measures to reduce risk of infection and severe disease, including ensuring that you have had a COVID-19 vaccination dose in the last 12 months, especially, if you are in an at-risk group,” stressed Dr. Van Kerkhove.

Vaccines availability has declined substantially over the last 12-18 months, WHO admits, because the number of producers of COVID-19 vaccines has recently decreased. “It is very difficult for them to maintain the pace,” Dr. Van Kerkhove explained. “And certainly, they don't need to maintain the pace that they had in 2021 and 2022. But let's be very clear, there is a market for COVID-19 vaccines that are out there.”

Nasal vaccines are still under development but could potentially address transmission, thereby reducing the risk of further variants, infection and severe disease.

“I am concerned, “ Dr. Van Kerkhove said. “With such low coverage and with such large circulation, if we were to have a variant that would be more severe, then the susceptibility of the at-risk populations to develop severe disease is huge,” Dr. Van Kerkhove warned.

Ends
[*/quote*]

[VanLaraklios]

5 Prozent der Weltbevölkerung sind definitiv erledigt.

400 Millionen Menschen weltweit haben LongCovid. Von der Gesamtbevölkerung der Erde sind das 5 Prozent!

Wer soll diese 5 Prozent versorgen?

Wenn man von nur 1 Person pro Erkranktem ausgeht, sind damit weitere 5 Prozent kaltgestellt. Das heißt: 10 Prozent der Weltbevölkerung sind weg vom Fenster.

Hier erst mal die neue Studie:

[*quote*]


https://pbs.twimg.com/card_img/1824428364662255616/OCYm0WJm?format=jpg&name=900x900

We estimated the global incidence of long COVID on the basis of meta-regression estimates that pool together all the available evidence. Considering the Institute for Health Metrics and Evaluation’s annual estimates of SARS-CoV-2 infections31,55,56,57,58,59 and assuming the lower risk estimate of 6.2% for long COVID at 3 months after infection31, a proportion symptomatic cases among infections of 65% (ref. 31), and a reduction in the risk of long COVID for 2022 and 2023 (to account for the combination of the putative lower severity of the Omicron variant and the mildly protective effect of vaccination)60, the estimated cumulative global incidence of long COVID was 65 million, 211 million, 337 million and 409 million in 2020, 2021, 2022 and 2023, respectively.
[*/quote*]

more:

nature medicine review articles
    Review Article
    Published: 09 August 2024
Long COVID science, research and policy
Ziyad Al-Aly, Hannah Davis, Lisa McCorkell, Letícia Soares, Sarah Wulf-Hanson, Akiko Iwasaki & Eric J. Topol
https://www.nature.com/articles/s41591-024-03173-6

Zur Veranschaulichung die Bevölkerungskurve, wie sie zur Zeit von Statista angegeben wird:



Quelle:
https://de.statista.com/statistik/daten/studie/1694/umfrage/entwicklung-der-weltbevoelkerungszahl/


Die Darstellung ist gepfuscht. Zwar sind am rechten Ende der Skala die Schritte von Jahr zu Jahr, aber links sind es 250 Jahre. Deswegen kann man schlecht schätzen für die Zeiten, in denen keine Jahreszahlen angegeben sind.

Wenn von 8000 Millionen die 400 LongCovid-Fälle runter sind, bleiben 7600 Millionen, was ungefähr 2017 erreicht wurde. Also ein Rückfall um mehr als 6 Jahre. Für die 400 Millionen Versorger geht es noch weitere Jahre zurück.

Noch hat das große Sterben nicht voll eingesetzt, was man auch an der immer noch steigenden Bevölkerungszahl sieht. Aber demnächst geht es 800 Millionen Menschen ernsthaft an den Kragen. Und das ist nur der Anfang....

[Krik]

https://content.govdelivery.com/accounts/USFDA/bulletins/3b0739b

[*quote*]
U.S. Food and Drug Administration sent this bulletin at 08/22/2024 02:01 PM EDT

USFDA
FDA Approves and Authorizes Updated mRNA COVID-19 Vaccines to Better Protect Against Currently Circulating Variants

US Food and Drug Administration
FDA Approves and Authorizes Updated mRNA COVID-19 Vaccines to Better Protect Against Currently Circulating Variants

Today, the U.S. Food and Drug Administration approved and granted emergency use authorization (EUA) for updated mRNA COVID-19 vaccines (2024-2025 formula) to include a monovalent (single) component that corresponds to the Omicron variant KP.2 strain of SARS-CoV-2. The mRNA COVID-19 vaccines have been updated with this formula to more closely target currently circulating variants and provide better protection against serious consequences of COVID-19, including hospitalization and death. Today’s actions relate to updated mRNA COVID-19 vaccines manufactured by ModernaTX Inc. and Pfizer Inc.

In early June, the FDA advised manufacturers of licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 formula) should be monovalent JN.1 vaccines. Based on the further evolution of SARS-CoV-2 and a rise in cases of COVID-19, the agency subsequently determined and advised manufacturers that the preferred JN.1-lineage for the COVID-19 vaccines (2024-2025 formula) is the KP.2 strain, if feasible.

“Vaccination continues to be the cornerstone of COVID-19 prevention,” said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research. “These updated vaccines meet the agency’s rigorous, scientific standards for safety, effectiveness, and manufacturing quality. Given waning immunity of the population from previous exposure to the virus and from prior vaccination, we strongly encourage those who are eligible to consider receiving an updated COVID-19 vaccine to provide better protection against currently circulating variants.”

The updated mRNA COVID-19 vaccines include Comirnaty and Spikevax, both of which are approved for individuals 12 years of age and older, and the Moderna COVID-19 Vaccine and Pfizer-BioNTech COVID-19 Vaccine, both of which are authorized for emergency use for individuals 6 months through 11 years of age.

What You Need to Know

    Unvaccinated individuals 6 months through 4 years of age are eligible to receive three doses of the updated, authorized Pfizer-BioNTech COVID-19 Vaccine or two doses of the updated, authorized Moderna COVID-19 Vaccine.
    Individuals 6 months through 4 years of age who have previously been vaccinated against COVID-19 are eligible to receive one or two doses of the updated, authorized Moderna or Pfizer-BioNTech COVID-19 vaccines (timing and number of doses to administer depends on the previous COVID-19 vaccine received).
    Individuals 5 years through 11 years of age regardless of previous vaccination are eligible to receive a single dose of the updated, authorized Moderna or Pfizer-BioNTech COVID-19 vaccines; if previously vaccinated, the dose is administered at least 2 months after the last dose of any COVID-19 vaccine.
    Individuals 12 years of age and older are eligible to receive a single dose of the updated, approved Comirnaty or the updated, approved Spikevax; if previously vaccinated, the dose is administered at least 2 months since the last dose of any COVID-19 vaccine.
    Additional doses are authorized for certain immunocompromised individuals ages 6 months through 11 years of age as described in the Moderna COVID-19 Vaccine and Pfizer-BioNTech COVID-19 Vaccine fact sheets.

Individuals who receive an updated mRNA COVID-19 vaccine may experience similar side effects as those reported by individuals who previously received mRNA COVID-19 vaccines and as described in the respective prescribing information or fact sheets. The updated vaccines are expected to provide protection against COVID-19 caused by the currently circulating variants. Barring the emergence of a markedly more infectious variant of SARS-CoV-2, the FDA anticipates that the composition of COVID-19 vaccines will need to be assessed annually, as occurs for seasonal influenza vaccines.

For today’s approvals and authorizations of the mRNA COVID-19 vaccines, the FDA assessed manufacturing and nonclinical data to support the change to include the 2024-2025 formula in the mRNA COVID-19 vaccines. The updated mRNA vaccines are manufactured using a similar process as previous formulas of these vaccines. The mRNA COVID-19 vaccines have been administered to hundreds of millions of people in the U.S., and the benefits of these vaccines continue to outweigh their risks.

On an ongoing basis, the FDA will review any additional COVID-19 vaccine applications submitted to the agency and take appropriate regulatory action.

The approval of Comirnaty (COVID-19 Vaccine, mRNA) (2024-2025 Formula) was granted to BioNTech Manufacturing GmbH. The EUA amendment for the Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula) was issued to Pfizer Inc.

The approval of Spikevax (COVID-19 Vaccine, mRNA) (2024-2025 Formula) was granted to ModernaTX Inc. and the EUA amendment for the Moderna COVID-19 Vaccine (2024-2025 Formula) was issued to ModernaTX Inc.
Related Information

    Comirnaty (COVID-19 Vaccine, mRNA) (2024-2025 Formula)
    Spikevax (COVID-19 Vaccine, mRNA) (2024-2025 Formula)
    Moderna COVID-19 Vaccine (2024-2025 Formula)
    Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula)
    FDA Resources for the Fall Respiratory Illness Season
    Updated COVID-19 Vaccines for Use in the United States Beginning in Fall 2024
    June 5, 2024, Meeting of the Vaccines and Related Biological Products Advisory Committee

Subscribe to updates from U.S. Food and Drug Administration
Email Addresse.g. name@example.com
[*/quote*]

[Krik]

Press release:

https://today.uic.edu/covid-virus-evolves-more-rapidly-in-the-central-nervous-system-than-in-the-lungs-study-finds/

[*quote*]
Updated: Aug 26, 2024 at 06:04 PM
UIC Today

COVID virus evolves more rapidly in the central nervous system than in the lungs, study finds

August 26, 2024

The coronavirus responsible for the COVID-19 pandemic evolves more rapidly in the brain than in the lungs, according to new research from University of Illinois Chicago and Northwestern University.

New viral variants created in the brain and other parts of the nervous system could also travel back to the lungs, where they could become transmissible, the researchers report in Nature Microbiology.
https://www.nature.com/articles/s41564-024-01786-8

That could spread new, dangerous variants of the virus.

A man in a gray collared shirt stands outdoors in front of tress and greenery.Justin Richner, assistant professor of microbiology and immunology. (Photo courtesy of Justin Richner)

“Potentially, this could be a source of novel variants of concern,” said Justin Richner, assistant professor of microbiology and immunology at UIC and co-lead author of the paper. “It could be that the virus is using these different tissue sites to evolve new mutations, and then those can traffic back into the respiratory tract and spread throughout the population.”

The study, conducted in mice, first tested how COVID-19 vaccination affects the mutation of viruses in the body. Five days after infection, researchers measured the number of viral variants present in different parts of the body. They were surprised to find more viral variation in the brain than in the lungs in both vaccinated and unvaccinated mice.

“The vaccination status didn’t really determine the virus evolution, but we observed differences in the virus sequence in the brain versus the lung,” Richner said. “That really set us on a totally unexpected trajectory.” 

Most mutations were in the gene for the viral spike protein, which the virus uses to enter and infect cells. Most changes were found in a region of the spike protein called the furin cleavage site.

“This site is of high interest because it is linked to the outbreak and transmissibility of the SARS-CoV-2 virus,” Richner said. “It leads to more enhanced transmission of the virus and why it was able to much more easily transmit through the entire population.”

However, most variants found in the brain disrupted the function of this spike protein site, producing strains that were less virulent when tested in subsequent experiments. The researchers hypothesized that the virus uses an alternative mechanism to infect cells in the central nervous system, driving the mutation of the new variants.

Despite the reduced virulence, researchers were alarmed by the ability of these viral variants to migrate from the central nervous system back to the lungs, where they could then potentially spread through the air to other individuals. The ability of the virus to rapidly evolve in immune-protected areas of the body, such as the brain or the testes, could drive future dangerous variants.

That possibility underscores the importance of vaccination, Richner said.

“This finding suggests that the vaccines are still important because the only way the virus reaches these distal tissues is if it establishes an infection and is able to replicate in the body,” Richner said. “The vaccines are important to prevent the virus from reaching some of those distal tissues and undergo diversification.”

In future work, the researchers hope to study how viruses travel from the central nervous system back to the lungs. They will also investigate potential links between the viral variants found in the brain and the neurological symptoms, such as “brain fog” and memory loss, associated with both acute and long COVID. 

The collaboration between Richner’s group and the research team of Judd Hultquist at Northwestern University highlights the close partnerships between Chicago research institutions established in the early days of the COVID-19 pandemic. 

“I think that this research really speaks to the strength of the Chicago virology community,” Richner said. “It was a truly collaborative project that would not be possible without both parties.”

In addition to Richner, UIC co-authors on the paper include Jacob Class, Jazmin Galván Achi, Laura Cooper, Sarah Lutz and Lijun Rong.

Contact
Rob Mitchum
rmitchum@uic.edu
Health Sciences Colleges, Research, UIC today   

UIC Today
Office of Strategic Marketing and Communications
601 S. Morgan St., 1320 UH, Chicago, IL 60607
uictoday@uic.edu

© 2024 The Board of Trustees of the University of Illinois
University of Illinois System Urbana-Champaign Springfield
[*/quote*]

[Dellbrock]

GENIAL! 


https://x.com/Yash25571056/status/1830012385903685832

[*quote*]
Hiroshi Yasuda (保田浩志) @Yash25571056

I told my colleagues that SARS-CoV-2 infection can make them careless, but they don't care.

12:38 AM · Sep 1, 2024
4,401 Views
[*/quote*]

[Dellbrock]

https://x.com/DataDrivenFP/status/1830040361538109624

[*quote*]
PeterLiepmannMDFAAFP #COVIDisAirborne 🇺🇸🇺🇦☮️  @DataDrivenFP

I tell people COVID infection damages their spatial ability, but they just stumble out.


https://pbs.twimg.com/media/GWWb05XbQAAjRCU?format=jpg&name=900x900

[ALT:]
Impaired copies of a complex figure by young professionals after mild Covid infections."researchers in Brazil found people who had mild COVID-19 symptoms showed “persistent cognitive impairment” months post-infection, where some were complaining of bumping into things or not being able to park the car due to altered depth perception and visual processing."

"it’s “really worrying” because the group’s mean age was 38 and mostly highly educated professionals such as physicians and nurses"

https://www.brainfacts.org/diseases-and-disorders/covid-19/2023/the-risks-of-even-mild-covid19-1-in-4-showing-cognitive-deficits-011723

Assessing risk shares features with other complex cognitive tasks.
https://www.manager-magazin.de/hbm/long-covid-and-the-economy-there-is-money-in-prevention-a-54022db9-428f-41d7-b71c-3f9befa58b0e?sara_ref=re-xx-cp-sh

Lifetime cumulative risk of Long Covid
https://interactive.spiegel.de/gra/ai2html/manager-magazin/2024/hbm0224/domke_e/img/domke_e-1-Midi.jpg
2:29 AM · Sep 1, 2024
·
14
 Views
[*/quote*]

[Krik]

Marke: 41.000

[Rhokia]

https://x.com/HarrySpoelstra/status/1837758972708651315

[*quote*]
--------------------------------------------
Harry Spoelstra @HarrySpoelstra

SARS-CoV-2 and HSV-1 Induce Amyloid Aggregation in Human CSF Resulting in Drastic Soluble Protein Depletion  #Preprint🤔

➡️ C19 isn't yor friend, hell NO!😬

🔥"Our results show that these viruses can physically induce amyloid aggregation of proteins in human CSF and result in soluble protein depletion, and thus providing a potential mechanism that may account for the association between persistent and latent/reactivating brain infections and NEURODEGENERATIVE diseases."
#BRAINDAMAGE  https://biorxiv.org/content/10.1101/2022.09.15.508120v2
Image



https://pbs.twimg.com/media/GYEIC4NWwAAd9Se?format=jpg&name=4096x4096

9:40 AM · Sep 22, 2024
4,004 Views

--------------------------------------------
Guenter GR @GrGuenter
2h
Myelin dysfunction resulting in neuronal amyloid deposition is  the hallmark of SSPE and Alzheimer. Sadly every new paper reporting SARS-Cov2 brain disorders is more and more pointing the fingers at possible Covid induced SSPE in children. We're going to see this in a few years.

--------------------------------------------
Guenter GR @GrGuenter
2h
Myelin Disorders and Covid (paper)

Myelin dysfunction is the hallmark of MS, Alzheimer, (MOGAD/MOG-EM) and SSPE.



https://pbs.twimg.com/card_img/1837794408055345152/yi0x8Jhk?format=jpg&name=900x900

Content cover image
https://link.springer.com/article/10.1007/s00415-021-10752-x

--------------------------------------------
Sven Magnusson @DocMagnusson
34m
Interessante Studie, die mögliche Verbindungen zwischen COVID-19, viralen Infektionen und neurodegenerativen Erkrankungen aufzeigt. Die Forschung zu den Auswirkungen von SARS-CoV-2 auf unsere Gesundheit ist ein wichtiger Bereich, den wir weiterverfolgen müssen.

[*/quote*]

[Wrastrolentiks]

https://pbs.twimg.com/media/GYLLYvoWoAAMzpd?format=jpg&name=4096x4096

Fauci hat Recht!

[Krik]

Ein Professor in Japan hat einen Artikel entdeckt über eine Studie in den Niederlanden. Das ist, verdammt nochmal, vor unserer Haustür!

Die Kinder beißen reihenweise ins Gras. Wie lange noch lassen die Bürger sich von ihren Regierungen umbringen?



https://x.com/Yash25571056/status/1839931717823672715

[*quote*]
Hiroshi Yasuda (保田浩志) @Yash25571056

From a study on pediatric Post-COVID-19 condition (PPCC) of 579 children, including 260 mild acute COVID (median age: 8 y/o), 60 severe COVID (1 y/o), and 256 tested negative (NT) children (8 y/o),
"At three months, 14.6% of the SARS-CoV-2 positive mild group (RR:6.31) and 29.2% of the severe group (RR:12.95) reported sequelae, versus 2.3% of the NT group..
Children with PPCC exhibited lower physical health-related quality of life scores and higher fatigue scores than the NT children.."

Infants can also acquire long COVID.

'Post-COVID-19 condition in children: epidemiological evidence stratified by acute disease severity'
https://nature.com/articles/s41390-024-03597-3
9:34 AM · Sep 28, 2024
535 Views
[*/quote*]




https://nature.com/articles/s41390-024-03597-3

[*/quote*]
nature pediatric research population study article
    article
    Population Study Article
    Published: 27 September 2024

Post-COVID-19 condition in children: epidemiological evidence stratified by acute disease severity

    Coen R. Lap, Caroline L. H. Brackel, Angelique M. A. M. Winkel, Simone Hashimoto, Milly Haverkort, Lieke C. E. Noij, Mattijs W. Alsem, Erik G. J. von Asmuth, Michiel A. G. E. Bannier, Emmeline P. Buddingh, Johannes B. van Goudoever, Lotte Haverman, Anke H. Maitland – van der Zee, Miriam G. Mooij, Kim Oostrom, Mariëlle W. Pijnenburg, Sanne Kloosterman, Lorynn Teela, Michiel Luijten, Adam J. Tulling, Gertjan Lugthart, Debby Bogaert, Giske Biesbroek, Marlies A. van Houten & Suzanne W. J. Terheggen-Lagro

Pediatric Research (2024)Cite this article

    Metrics details

Abstract
Background

To determine the prevalence of pediatric Post-COVID-19 condition (PPCC), identify risk factors, and assess the quality of life in children with differing severities of acute COVID-19.
Methods

During a prospective longitudinal study with a 1-year follow-up, we compared non-hospitalized (mild) and hospitalized (severe) COVID-19 cases to a negatively tested control group.
Results

579 children were included in this study. Of these, 260 had mild acute disease (median age:8, IQR:6–10), 60 had severe acute disease (median age:1, IQR:0.1–4.0), and 259 tested negative for SARS-CoV-2 (NT) (median age:8, IQR:5-10).

At three months, 14.6% of the SARS-CoV-2 positive mild group (RR:6.31 (CI 95%: 2.71–14.67)) and 29.2% of the severe group (RR:12.95 (CI 95%: 5.37–31.23)) reported sequelae, versus 2.3% of the NT group. PPCC prevalence in the mild group decreased from 16.1% at one month to 4.4% at one year. Children with PPCC exhibited lower physical health-related quality of life scores and higher fatigue scores than the NT children.
Conclusions

Severe acute COVID-19 in children leads to a higher PPCC prevalence than in mild cases. PPCC prevalence decreases over time. Risk factors at three months include prior medical history, hospital admission, and persistent fatigue one month after a positive test.
Impact

    We demonstrate children with severe COVID-19 are more likely to develop Post-COVID-19 condition than those with mild or no infections, and highlights the risk factors.

    Here we have stratified by acute disease severity, prospectively included a negative control group, and have demonstrated the heterogeneity in prevalence when utilizing various recent definitions of post-COVID.

    Identifying risk factors for pediatric post-COVID and highlighting the heterogeneity in prevalence based on various current definitions for post-COVID should aid in correctly identifying potential pediatric post-COVID cases, aiding in early intervention.

This is a preview of subscription content, access via your institution
[...]

Data availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
References

    Brodin, P. Immune responses to SARS-CoV-2 infection and vaccination in children. Semin Immunol. 69, 101794 (2023).

    Article
     
    CAS
     
    PubMed
     
    Google Scholar
     

    RIVM. Actuele informatie over het nieuwe coronavirus (COVID-19). Actuele informatie over het nieuwe coronavirus (COVID-19) | RIVM 1–1 https://www.rivm.nl/coronavirus-covid-19/actueel%0A. https://www.rivm.nl/nieuws/actuele-informatie-over-coronavirus (2020).

    StatLine. Jongeren (0 tot 25 jaar); geslacht, leeftijd, migratieachtergrond, regio’s. StatLine: Jeugdmonitor https://jmopendata.cbs.nl/#/JM/nl/dataset/71009ned/table?dl=21563 (2023).

    Wulf Hanson, S. et al. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA 328, 1604–1615 (2022).

    Article
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Parisi, G. F. et al. Cross-sectional survey on long term sequelae of pediatric COVID-19 among Italian pediatricians. Children (Basel) 8, 769 (2021).

    Osmanov, I. M. et al. Risk factors for long covid in previously hospitalised children using the ISARIC Global follow-up protocol: A prospective cohort study. Eur. Respir. J. 59, (2022).

    Borch, L., Holm, M., Knudsen, M., Ellermann-Eriksen, S. & Hagstroem, S. Long COVID symptoms and duration in SARS-CoV-2 positive children - a nationwide cohort study. Eur. J. Pediatr. 181, 1597–1607 (2022).

    Article
     
    CAS
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Erol, N., Alpinar, A., Erol, C., Sari, E. & Alkan, K. Intriguing new faces of Covid-19: persisting clinical symptoms and cardiac effects in children. Cardiol. Young-. 32, 1085–1091 (2022).

    Article
     
    PubMed
     
    Google Scholar
     

    Asadi-Pooya, A. A. et al. Long COVID in children and adolescents. World J. Pediatr. 17, 495–499 (2021).

    Article
     
    CAS
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Smane, L., Roge, I., Pucuka, Z. & Pavare, J. Clinical features of pediatric post-acute COVID-19: a descriptive retrospective follow-up study. Italian J. Pediatr. 47, 177 https://doi.org/10.1186/s13052-021-01127-z (2021).

    Buonsenso, D. et al. Preliminary evidence on long COVID in children. Acta Paediatr. 110, 2208–2211 (2021).

    Article
     
    CAS
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Kikkenborg Berg, S. et al. Long COVID symptoms in SARS-CoV-2-positive children aged 0-14 years and matched controls in Denmark (LongCOVIDKidsDK): a national, cross-sectional study. Lancet Child Adolesc. Health 6, 614–623 (2022).

    Article
     
    CAS
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Heching, H. J. et al. Electrocardiographic changes in non-hospitalised children with COVID-19. Cardiol. Young-. 32, 1910–1916 (2022).

    Article
     
    PubMed
     
    Google Scholar
     

    Stephenson, T., Shafran, R. & Ladhani, S. N. Long COVID in children and adolescents. Curr. Opin. Infect. Dis. 35, 461–467 (2022).

    Article
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Roge, I. et al. Comparison of Persistent Symptoms After COVID-19 and Other Non-SARS-CoV-2 Infections in Children. Front Pediatr. 9, 752385 (2021).

    Article
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Zimmermann, P., Pittet, L. F. & Curtis, N. How Common is Long COVID in Children and Adolescents? Pediatr. Infect. Dis. J. 40, e482–e487 (2021).

    Article
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Hahn, L. M. et al. Post–COVID-19 Condition in Children. JAMA Pediatr. 177, 1226–1228 (2023).

    Article
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Bygdell, M., Kindblom, J. M., Martikainen, J., Li, H. & Nyberg, F. Incidence and Characteristics in Children with Post–COVID-19 Condition in Sweden. JAMA Netw. Open 6, e2324246 (2023).

    Article
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Funk, A. L. et al. Post–COVID-19 Conditions Among Children 90 Days After SARS-CoV-2 Infection. JAMA Netw. Open 5, e2223253 (2022).

    Article
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Brackel, C. L. H. et al. Pediatric long-COVID: An overlooked phenomenon? Pediatr. Pulmonol. 56, 2495–2502 (2021).

    Article
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Izquierdo-Pujol, J. et al. Post COVID-19 Condition in Children and Adolescents: An Emerging Problem. Front Pediatr. 10, 894204 (2022).

    Article
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Molteni, E. et al. Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2. Lancet Child Adolesc. Health 5, 708–718 (2021).

    Article
     
    CAS
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Buonsenso, D. et al. Post-COVID Condition in Adults and Children Living in the Same Household in Italy: A Prospective Cohort Study Using the ISARIC Global Follow-Up Protocol. Front Pediatr. 10, 834875 (2022).

    Article
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Gupta, M., Gupta, N. & Esang, M. Long COVID in children and adolescents. Prim Care Companion CNS Disord 24, 21r03218 (2022).

    Pellegrino, R., Chiappini, E., Licari, A., Galli, L. & Marseglia, G. L. Prevalence and clinical presentation of long COVID in children: a systematic review. Eur. J. Pediatr. 181, 3995–4009 (2022).

    Article
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Pierce, C. A. et al. COVID-19 and children. Science (1979) 377, 1144–1149 (2022).

    Google Scholar
     

    Tulling, A. J. et al. Severe Pediatric COVID-19 and Multisystem Inflammatory Syndrome in Children From Wild-type to Population Immunity: A Prospective Multicenter Cohort Study With Real-time Reporting. Pediatr. Infect. Dis. J. https://doi.org/10.1097/INF.0000000000004098 (2023).

    National Institute for Public Health and the Environment (RIVM). Varianten van het coronavirus SARS-CoV-2. https://www.rivm.nl/corona/actueel/virusvarianten.

    National Institute for Health and Care Excellence, Practitioners, R. C. of G. & Scotland, H. I. COVID-19 rapid guideline: managing the long-term effects of COVID-19. NICE Guidelines 1–35 (2020).

    Varni, J. W. The PedsQL Measurement Model. https://www.pedsql.org/ (2023).

    van Muilekom, M. M. et al. Psychometric properties of the Patient-Reported Outcomes Measurement Information System (PROMIS®) Pediatric Anger Scale in the Dutch general population. Psychol. Assess. 33, 1261–1266 (2021).

    Article
     
    PubMed
     
    Google Scholar
     

    Peersmann, S. H. M. et al. Psychometric properties and CAT performance of the PROMIS pediatric sleep disturbance, sleep-related impairment, and fatigue item banks in Dutch children and adolescents. Psychol. Assess. 34, 860–869 (2022).

    Article
     
    PubMed
     
    Google Scholar
     

    PROMIS. https://www.healthmeasures.net/explore-measurement-systems/promis.

    Klaufus, L. H. et al. Psychometric properties of the Dutch-Flemish PROMIS(®) pediatric item banks Anxiety and Depressive Symptoms in a general population. Qual. Life Res 30, 2683–2695 (2021).

    Article
     
    CAS
     
    PubMed
     
    Google Scholar
     

    Luijten, M. A. J., van Litsenburg, R. R. L., Terwee, C. B., Grootenhuis, M. A. & Haverman, L. Psychometric properties of the Patient-Reported Outcomes Measurement Information System (PROMIS®) pediatric item bank peer relationships in the Dutch general population. Qual. Life Res 30, 2061–2070 (2021).

    Article
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Morello, R. et al. Risk factors for post-COVID-19 condition (Long Covid) in children: a prospective cohort study. EClinicalMedicine 59, 101961 (2023).

    Article
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Di Sante, G. et al. Immunopathology of SARS-CoV-2 infection: a focus on t regulatory and b cell responses in children compared with adults. Children 9, 681 (2022).

    Long COVID Kids. Feedback on the Long Covid Clinics. Preliminary healthcare experiences survey findings. https://www.longcovidkids.org/post/feedback-on-the-long-covid-clinics-preliminary-healthcare-experiences-survey-findings#viewer-dge2d (2023).

    Buonsenso, D. et al. Paediatric long COVID studies should focus on clinical evaluations that examine the impact on daily life not just self-reported symptoms. Acta Paediatr. 113, 778–780 (2024).

    Article
     
    PubMed
     
    Google Scholar
     

    Buonsenso, D. et al. Long-term outcomes of pediatric infections: from traditional infectious diseases to long Covid. Future Microbiol 17, 551–571 (2022).

    Article
     
    CAS
     
    PubMed
     
    Google Scholar
     

    Morrow, A. K. et al. Postacute/Long COVID in Pediatrics: Development of a Multidisciplinary Rehabilitation Clinic and Preliminary Case Series. Am. J. Phys. Med Rehabil. 100, 1140–1147 (2021).

    Article
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    NvK. NVK Handreiking Post-COVID Syndroom. https://www.nvk.nl/themas/kwaliteit/overige-kennisdocumenten/document?documentregistrationid=170917888 (2022).

    A clinical case definition for post COVID-19 condition in children and adolescents by expert consensus, 16 February 2023. https://www.who.int/publications/i/item/WHO-2019-nCoV-Post-COVID-19-condition-CA-Clinical-case-definition-2023-1.

    World Health Organization. a Clinical Case Definition for Post Covid-19 Condition in Children and Adolescents By Expert Consensus. 1–99 (2023).

    Baldi, F. et al. Cardiopulmonary Exercise Testing in Children With Long COVID: A Case-controlled Study. Pediatr. Infect. Dis. J. (2024) https://doi.org/10.1097/INF.0000000000004371.

    Delogu, A. B. et al. Autonomic cardiac function in children and adolescents with long COVID: a case-controlled study. Eur. J. Pediatr. 183, 2375–2382 (2024).

    Article
     
    CAS
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Buonsenso, D., Morello, R., De Rose, C., Spera, F. & Baldi, F. Long-term outcome of a child with postcovid condition: Role of cardiopulmonary exercise testing and 24-h Holter ECG to monitor treatment response and recovery. Pediatr. Pulmonol. 58, 2944–2946 (2023).

    Article
     
    PubMed
     
    Google Scholar
     

    Spera, F. R. et al. Post-COVID Postural Orthostatic Tachycardia Syndrome and Inappropriate Sinus Tachycardia in the Pediatric Population. Curr. Clin. Microbiol Rep. 11, 115–125 (2024).

    Article
     
    Google Scholar
     

    Davis, H. E., McCorkell, L., Vogel, J. M. & Topol, E. J. Long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 21, 133–146 (2023).

    Article
     
    CAS
     
    PubMed
     
    PubMed Central
     
    Google Scholar
     

    Chen, E. Y., Morrow, A. K. & Malone, L. A. Exploring the Influence of Pre-Existing Conditions and Infection Factors on Pediatric Long COVID Symptoms and Quality of Life. Am. J. Phys. Med. Rehabil. (2023) https://doi.org/10.1097/PHM.0000000000002363.

Download references
Acknowledgements

For the collection of data for the PoCoCoChi study, we would like to acknowledge and thank the Public Health Service (GGD) Kennemerland. For the collection of the COPP Clinical data a large group of medical professionals and researchers (listed below) cooperated to make the data-collection possible. We Would like to acknowledge these as the ‘COPP study group’, the complete list of members can be found in the supplemental Digital Content Table E12. 1. Research grant for pediatric COVID research: ZonMw (10430072110007 and 10430102110009). 2. Research grant for pediatric COVID research: Bontius Stichting and the Leiden University Fund. 3. SAB (Stichting Steun Astma Bestrijding) Grant.
Author information
Author notes

    These authors contributed equally: Coen R. Lap, Caroline L. H. Brackel.

    These authors jointly supervised this work: Marlies A. van Houten, Suzanne W.J. Terheggen-Lagro.

Authors and Affiliations

    Department of Pediatrics – Van Houten research group, Spaarne Gasthuis, Hoofddorp and Haarlem, Haarlem, The Netherlands

    Coen R. Lap, Angelique M. A. M. Winkel & Marlies A. van Houten

    Department of Pediatric Pulmonology and Allergy, Emma Children’s Hospital, Amsterdam University Medical Centre (Amsterdam UMC), University of Amsterdam (UvA), Amsterdam, The Netherlands

    Coen R. Lap, Caroline L. H. Brackel, Angelique M. A. M. Winkel, Simone Hashimoto, Lieke C. E. Noij, Anke H. Maitland – van der Zee & Suzanne W. J. Terheggen-Lagro

    Department of Pediatric Immunology and Infectious Diseases, Wilhelmina Children’s Hospital and University Medical Centre Utrecht, Utrecht, The Netherlands

    Coen R. Lap & Debby Bogaert

    Department of Pediatrics, Tergooi Medical Centrum, Hilversum, The Netherlands

    Caroline L. H. Brackel

    Department of Pulmonary Medicine, Amsterdam UMC University of Amsterdam, Amsterdam, The Netherlands

    Simone Hashimoto & Anke H. Maitland – van der Zee

    Department of Infection Prevention and Control, Public Health Service (GGD) Kennemerland, Haarlem, The Netherlands

    Milly Haverkort

    Willem Alexander Children’s Hospital, Leiden University Medical Centre, Leiden, The Netherlands

    Erik G. J. von Asmuth, Emmeline P. Buddingh, Adam J. Tulling & Gertjan Lugthart

    Department of Pediatric Nephrology, Sophia Children’s Hospital, Erasmus MC, Rotterdam, The Netherlands

    Miriam G. Mooij

    Division of Pediatric Respiratory Medicine and Allergology, Department of Pediatrics, Erasmus MC -Sophia Children’s Hospital, Rotterdam, The Netherlands

    Mariëlle W. Pijnenburg & Sanne Kloosterman

    Division of Pediatric Respiratory Medicine, Department of Pediatrics, MosaKids Children’s Hospital, Maastricht University Medical Centre, Maastricht, The Netherlands

    Michiel A. G. E. Bannier

    Department of Pediatrics, Emma Children’s Hospital, Amsterdam University Medical Centre (Amsterdam UMC), University of Amsterdam (UvA), Amsterdam, The Netherlands

    Johannes B. van Goudoever

    Child and Adolescent Psychiatry & Psychosocial Care, Emma Children’s Hospital, Amsterdam University Medical Centre (Amsterdam UMC), University of Amsterdam (UvA), Amsterdam, The Netherlands

    Lotte Haverman, Kim Oostrom, Lorynn Teela & Michiel Luijten

    Department of Rehabilitation Medicine, Amsterdam Movement Sciences, Amsterdam University Medical Centre (Amsterdam UMC), University of Amsterdam (UvA), Amsterdam, The Netherlands

    Mattijs W. Alsem

    Centre for Inflammation Research, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh, UK

    Debby Bogaert

    Department of Pediatric Immunology, Rheumatology and Infectious Disease, Emma Children’s Hospital, Amsterdam University Medical Centre (Amsterdam UMC), University of Amsterdam (UvA), Amsterdam, The Netherlands

    Giske Biesbroek

    Amsterdam Public Health, Mental Health and Digital Health, Amsterdam, The Netherlands

    Lotte Haverman, Lorynn Teela & Michiel Luijten

    Amsterdam Reproduction and Development, Child Development, Amsterdam, The Netherlands

    Lotte Haverman, Lorynn Teela & Michiel Luijten

Contributions

Coen R. Lap and Caroline L.H. Brackel are responsible for the conception and design of the study, designed the data collection instruments, coordinated and supervised data collection, analyzed and interpreted the data, drafted, and critically reviewed and revised the manuscript for important intellectual content. Angelique M.A.M. Winkel, dr. Simone Hashimoto, Lieke C.E. Noij, Milly Haverkort, dr. Mattijs W. Alsem, Erik G.J. von Asmuth, dr. Michiel A.G.E. Bannier, dr Emmeline P. Buddingh, Adam J. Tulling, and dr. Gertjan Lugthart are responsible for the conception and design of the study, designed the data collection instruments, coordinated and supervised data collection, and critically reviewed and revised the manuscript for important intellectual content. Dr. Johannes B. van Goudoever, dr Lotte Haverman, dr. Miriam G. Mooij, dr. Kim Oostrom, dr. Mariëlle W. Pijnenburg, and Sanne Kloosterman coordinated and supervised data collection, drafted, and critically reviewed and revised the manuscript for important intellectual content. Lorynn Teela and dr. Michiel Luijten designed the data collection instruments, coordinated and supervised data collection, and critically reviewed and revised the manuscript for important intellectual content. dr. Anke H. Maitland – van der Zee, Dr. Debby Bogaert, dr. Giske Biesbroek, dr. Marlies A. van Houten, and dr. Suzanne W.J. Terheggen-Lagro are responsible for the conception and design of the study, designed the data collection instruments, coordinated and supervised data collection, and critically reviewed and revised the manuscript for important intellectual content. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.
Corresponding author

Correspondence to Coen R. Lap.
Ethics declarations
Competing interests

The authors declare no competing interests.
Informed consent

Patient consent was required and obtained prior to inclusion in both the PoCoCoChi and COPP studies.
Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Supplementary information
Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions
About this article
Check for updates. Verify currency and authenticity via CrossMark
Cite this article

Lap, C.R., Brackel, C.L.H., Winkel, A.M.A.M. et al. Post-COVID-19 condition in children: epidemiological evidence stratified by acute disease severity. Pediatr Res (2024). https://doi.org/10.1038/s41390-024-03597-3

Download citation

    Received22 February 2024

    Revised18 July 2024

    Accepted05 September 2024

    Published27 September 2024

    DOIhttps://doi.org/10.1038/s41390-024-03597-3

Access through your institution
Buy or subscribe

    Abstract
    Data availability
    References
    Acknowledgements
    Author information
    Ethics declarations
    Additional information
    Supplementary information
    Rights and permissions
    About this article

Advertisement

Pediatric Research (Pediatr Res) ISSN 1530-0447 (online) ISSN 0031-3998 (print)
[*/quote*]

[Yuriki]

https://pbs.twimg.com/media/GYjOVFAXMAA4lWj?format=jpg&name=900x900

[Ayumi]

https://x.com/TheVertlartnic/status/1840803974150078550

[*quote*]
The Vertlartnic @TheVertlartnic

Could Dying Of Covid Protect You From A Severe Case Of Flu?

A funeral home offers an urn of cremated ashes that is now immune to flu Headline: Could Dying Of Covid Protect You From A Severe Case Of Flu? Story by Peter Pepper and Chaz W. Pasta Photo: Adobe File #: 325339932



https://pbs.twimg.com/media/GYvZCp0WYAAeBPF?format=jpg&name=900x900

7:20 PM · Sep 30, 2024
38.8K Views
[*/quote*]